Despite notable advances in the treatment of sJIA over the past 2 decades, particularly with the introduction of biologic therapies targeting key cytokines, such as IL-1 and IL-6 inhibitors, access to these medications, especially IL-1 inhibitors, remains limited in many Latin American countries due to their high costs, which vary across the region [4, 19]. Here, IL1B is linked to systemic-onset juvenile idiopathic arthritis.